SYNACT — SynAct Pharma AB Share News
0.000.00%
Last trade - 00:00- SEK821.62m
- SEK756.91m
Brief: SynAct Pharma Q3 Adjusted EPS SEK -1
Brief: Synact Pharma Announces Additional Data From Expand P2b Clinical Trial
Brief: SynAct Pharma Identifies Sub-Population Of Patients Responding To Resomelagon
Brief: Synact Pharma Announces Top Line Data From Expand P2b Clinical Trial
Brief: SynAct Pharma Completes Dosing In Part A Of Combined Phase 2a/b Resolve Study Of Resomelagon (AP1189) In Rheumatoid Arthritis (RA)
Brief: SynAct Pharma Q2 Net Income at SEK -43.511 Million
Brief: Synact Pharma Announces Completion Of Dosing In Phase 2B Expand Study
Brief: SynAct Pharma Appoints Björn Westberg As CFO
Brief: SynAct Pharma Q1 Adj. Loss per Share at EPS SEK 1.59
Brief: SynAct Pharma Appoints Torbjørn Bjerke As New CEO
Brief: SynAct Pharma Affiliate TXP Pharma Gets Granted Patent In Canada
Brief: Synact Pharma CFO Patrik Renblad Resigns
Brief: SynAct Pharma's COO Sells Shares To Cover Tax On Holdings
Brief: SynAct Pharma To Acquire TXP Pharma For SEK 136 Mln
Brief: Synact Pharma Carries Out Directed Share Issue Of SEK 80 Mln
Brief: Synact Pharma Q3 Loss After Tax At SEK 23.9 Mln
Brief: SynAct Pharma Receives IND Clearance From FDA
Brief: SynAct Pharma: Approval Of Amended Study Protocol For Phase 2a Study In iMN
Brief: SynAct Says CTA Approves For Phase 2B Study Expand